(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane ...

The PSA progression free survival in Arm A was 2.6 months versus 2.5 months in Arm B, and radiologic progression free survival was 2.1 months and 1.9 months in arm A and B, respectively. The median ...

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...

In the randomized dose-expansion phase of a Phase 1 study (NCT03460977), the combination of mevrometostat (1250 mg twice daily on an empty stomach) and enzalutamide (160 mg once daily) demonstrated ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...

Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and Bladder. Dr. Brendan Raizenne presented Poster 4578: Prognostic utility ...

Dr. Nicholas James presented a study assessing a multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Kevin Zarrabi discussing the molecular characterization of STEAP1 and STEAP2 in advanced prostate cancer. STEAP 1 and 2 ...

Dr. Angela Jia discussed How Better Treatments and Better Selection Can Improve Patient Outcomes in Localized Prostate Cancer. Dr. Jia discussed two important abstracts presented during the session: ...

AURKA inhibitors might enhance outcomes of metastatic prostate cancer treated with androgen receptor pathway inhibitors by intensifying androgen receptor inhibition, increasing DNA-damage-related cell ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Matthew Siskin discussing real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) ...